Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma.
The combination of etoposide and cis-platinum was evaluated in the treatment of advanced ovarian cancer. Of 13 treated patients, 4 demonstrated complete clinical responses and 3 demonstrated partial clinical responses. The mean progression free interval was 14 months+ for the complete responders and 8.3+ months for the partial responders. The 100 mg/m2 dose of etoposide appears to be critical in attaining response. This etoposide and cisplatinum combination appears to be effective as a salvage regimen in ovarian carcinoma.
Dottino
P R
PR
Goodman
H M
HM
Kredentser
D
D
Rosenberg
M
M
Cohen
C J
CJ
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology
D005047:Etoposide; D002945:Cisplatin